PALIPERIDONE PALMITATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352	NDA	Shandong Luye Pharmaceutical Co., Ltd.	72526-105-11	1 SYRINGE, GLASS in 1 KIT (72526-105-11) / .25 mL in 1 SYRINGE, GLASS	2024-12-10
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352	NDA	Shandong Luye Pharmaceutical Co., Ltd.	72526-106-11	1 SYRINGE, GLASS in 1 KIT (72526-106-11) / .5 mL in 1 SYRINGE, GLASS	2024-12-10
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352	NDA	Shandong Luye Pharmaceutical Co., Ltd.	72526-107-11	1 SYRINGE, GLASS in 1 KIT (72526-107-11) / .75 mL in 1 SYRINGE, GLASS	2024-12-10
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352	NDA	Shandong Luye Pharmaceutical Co., Ltd.	72526-108-11	1 SYRINGE, GLASS in 1 KIT (72526-108-11) / 1 mL in 1 SYRINGE, GLASS	2024-12-10
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352	NDA	Shandong Luye Pharmaceutical Co., Ltd.	72526-109-11	1 SYRINGE, GLASS in 1 KIT (72526-109-11) / 1.5 mL in 1 SYRINGE, GLASS	2024-12-10
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report identifies key suppliers and details the manufacturing landscape for paliperidone palmitate, an antipsychotic medication used for schizophrenia and schizoaffective disorder. The analysis focuses on active pharmaceutical ingredient (API) manufacturing, notable contract manufacturing organizations (CMOs), and the supply chain for critical intermediates.

What is Paliperidone Palmitate?

Paliperidone palmitate is an injectable long-acting atypical antipsychotic. It is the palmitate ester prodrug of paliperidone, which is the active metabolite of risperidone. The palmitate ester form provides a slow release of paliperidone from the injection site, allowing for less frequent dosing, typically once monthly or every three months. This extended-release profile is achieved through intramuscular injection, where the ester is gradually hydrolyzed in vivo to release the active drug.

The primary therapeutic indications for paliperidone palmitate are:

Schizophrenia in adults and adolescents 12 years of age and older.
Schizoaffective disorder in adults.

Key marketed formulations include INVEGA SUSTENNA® (1-month injection) and INVEGA TRINZA® (3-month injection), developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Extended-release formulations require specific manufacturing processes to ensure precise particle size distribution, suspension stability, and controlled release characteristics.

Key Manufacturers and Suppliers of Paliperidone Palmitate API

The manufacturing of paliperidone palmitate API involves multi-step organic synthesis. The complexity of the molecule and the stringent quality requirements for pharmaceutical APIs necessitate specialized manufacturing capabilities. Key suppliers are generally large, established API manufacturers with expertise in complex synthetic routes and regulatory compliance.

Primary API Manufacturers:

Johnson & Johnson (Janssen Pharmaceuticals): As the innovator company, J&J/Janssen maintains significant in-house API manufacturing capabilities for paliperidone palmitate to supply its branded products. This vertical integration ensures control over supply and quality for their proprietary formulations. Specific details regarding their API production sites are proprietary but are known to adhere to cGMP standards.
Major Generic API Manufacturers: Several global API manufacturers are authorized or have developed non-infringing synthetic routes to produce paliperidone palmitate for the generic market. These companies often operate large-scale facilities and have extensive experience in producing complex APIs for regulated markets.
- Sun Pharmaceutical Industries Ltd.: A leading Indian pharmaceutical company with a strong API manufacturing base. Sun Pharma has a broad portfolio of complex generics and intermediates. Their manufacturing facilities are US FDA, EMA, and other regulatory agency approved.
- Lupin Ltd.: Another prominent Indian pharmaceutical company with significant API manufacturing capacity. Lupin is known for its expertise in developing and manufacturing difficult-to-make APIs and finished dosage forms. They operate multiple cGMP-compliant facilities.
- Dr. Reddy's Laboratories: A global pharmaceutical company with integrated operations, including API manufacturing. Dr. Reddy's has a robust pipeline and manufacturing network for various therapeutic areas, including CNS drugs. Their API sites are regularly inspected by major regulatory bodies.
- Teva Pharmaceutical Industries Ltd.: A major global generic pharmaceutical company with substantial API manufacturing capabilities. Teva's expertise spans a wide range of APIs, and they are a significant player in the global API supply chain.
- Zydus Lifesciences Ltd. (formerly Cadila Healthcare): An Indian multinational pharmaceutical company with integrated manufacturing operations from APIs to finished formulations. Zydus has a strong focus on complex generics and specialized APIs.

Note: The specific API manufacturers supplying paliperidone palmitate can fluctuate based on patent expiry, regulatory approvals, and supply agreements. Manufacturers often produce APIs for both the innovator and generic markets under contract.

Contract Manufacturing Organizations (CMOs)

Beyond direct API synthesis, CMOs play a crucial role in the manufacturing of paliperidone palmitate, particularly in the formulation and fill-finish stages for both branded and generic products. These organizations provide specialized expertise, capacity, and regulatory compliance.

Key CMOs Involved in Paliperidone Palmitate Manufacturing (Formulation & Fill-Finish):

Catalent: A leading global provider of drug development and delivery technologies. Catalent offers comprehensive services, including sterile manufacturing, complex formulation development, and fill-finish operations for injectable drugs. Their capabilities are well-suited for long-acting injectable (LAI) formulations like paliperidone palmitate.
Lonza: A global partner to the pharmaceutical, biotech, and nutrition industries. Lonza has extensive expertise in the development and manufacturing of biopharmaceuticals and complex small molecules, including sterile injectable products. They operate multiple cGMP facilities globally.
Patheon (part of Thermo Fisher Scientific): A significant global CDMO offering end-to-end services from development to commercial manufacturing. Patheon has a strong track record in sterile injectable manufacturing and is equipped to handle complex formulations and specialized delivery systems.
Recipharm: A contract development and manufacturing organization that offers services for pharmaceutical products. Recipharm has capabilities in sterile manufacturing and can handle the production of complex injectable formulations.

CMOs involved in API Synthesis/Intermediates: While major API manufacturers often produce their own API, smaller or specialized CMOs might be involved in the synthesis of key intermediates or specific steps of the paliperidone palmitate manufacturing process. Identifying these specific CMOs is challenging as it often involves proprietary contractual relationships. However, companies with strong expertise in:

Chiral Synthesis: Given the complexity of paliperidone, specific chiral intermediates might require specialized synthesis.
Esterification: The formation of the palmitate ester is a critical step.
Micronization and Particle Engineering: For controlled release, precise particle size is paramount.

Manufacturing Process and Supply Chain Considerations

The manufacturing of paliperidone palmitate is a complex, multi-step process requiring specialized expertise and stringent quality control.

Key Manufacturing Stages:

Paliperidone Synthesis: The synthesis of paliperidone itself is a multi-step organic chemical process, starting from commercially available raw materials. This involves several reactions to build the core benzisoxazole structure and the piperidine ring.
Palmitoylation: Paliperidone is then reacted with palmitoyl chloride or a similar palmitoylating agent to form the ester prodrug, paliperidone palmitate. This is a critical step that requires precise control of reaction conditions to ensure high yield and purity.
Purification: The crude paliperidone palmitate is purified through crystallization and other separation techniques to remove impurities and achieve the required pharmaceutical grade.
Particle Size Control: For long-acting injectable formulations, the particle size distribution of paliperidone palmitate API is critical for controlling the drug release rate. This often involves milling processes such as jet milling or controlled crystallization to achieve the desired particle size range, typically in the low micron range (e.g., 1-10 microns).
Formulation: The API is then formulated into a sterile suspension. This involves suspending the micronized paliperidone palmitate particles in a suitable vehicle, typically an aqueous solution containing suspending agents, emulsifiers, and buffers. Common vehicles might include polysorbate 20, polyethylene glycol, and sodium chloride.
Sterile Fill-Finish: The formulated suspension is then aseptically filled into sterile vials or pre-filled syringes. This is a highly controlled process to maintain sterility and prevent microbial contamination.
Lyophilization (if applicable): While paliperidone palmitate is typically formulated as a ready-to-use suspension, some LAI drugs utilize lyophilization. However, for paliperidone palmitate, it's typically not lyophilized.

Critical Raw Materials and Intermediates:

The supply chain for paliperidone palmitate relies on the availability of several key raw materials and intermediates. The complexity of the synthesis means that disruptions at any stage can impact the final API production.

Precursors for Paliperidone Synthesis: These are various chemical compounds used as starting materials for the multi-step synthesis of paliperidone. Examples might include derivatives of benzisoxazole, piperidine, and other heterocyclic compounds.
Palmitic Acid Derivatives: Palmitic acid itself or activated derivatives like palmitoyl chloride are essential for the esterification step. Palmitic acid is a common saturated fatty acid derived from palm oil or other sources.
Solvents and Reagents: A wide array of organic solvents (e.g., methanol, ethanol, isopropyl alcohol, ethyl acetate, toluene, N,N-dimethylformamide) and reagents (e.g., bases, acids, catalysts, coupling agents) are used throughout the synthesis and purification process.
Excipients for Formulation: These are inactive ingredients used to formulate the final drug product, including suspending agents, wetting agents, emulsifiers, tonicity modifiers, and buffers. Examples include polysorbate 20, polyethylene glycols (PEGs), sodium chloride, and buffering salts.

Supply Chain Risks and Mitigation:

Geopolitical Factors: Reliance on specific regions for key intermediates or raw materials can expose the supply chain to geopolitical instability, trade disputes, or export restrictions.
Regulatory Changes: Evolving regulatory requirements for API manufacturing, environmental standards, or impurity limits can necessitate process changes and impact supply.
Quality Control Issues: Stringent quality control is vital at every step. Any lapse can lead to batch rejection and supply disruptions.
Intellectual Property: Patent landscapes for both the API and the manufacturing process can influence market entry and supplier choices for generic manufacturers.
Natural Disasters and Pandemics: Unforeseen events can disrupt production at manufacturing sites or impact transportation and logistics.

Mitigation strategies often include:

Dual Sourcing: Establishing relationships with multiple qualified suppliers for critical raw materials and intermediates.
Geographic Diversification: Sourcing from manufacturers located in different geographical regions.
Robust Auditing and Quality Agreements: Implementing comprehensive quality agreements with suppliers and conducting regular audits to ensure compliance.
Inventory Management: Maintaining adequate safety stocks of critical materials and finished APIs.
Continuous Process Improvement: Investing in process R&D to optimize yields, reduce waste, and enhance control.

Intellectual Property and Market Dynamics

The intellectual property landscape for paliperidone palmitate is dominated by patents originally held by Johnson & Johnson. As these patents expire, the market opens for generic manufacturers.

Patent Expirations: The core patents protecting paliperidone palmitate, including formulation patents and method of manufacturing patents, have either expired or are nearing expiration in major markets. This has led to increased generic competition. For instance, US patents related to formulations and methods of treatment have been subject to litigation and expiration timelines.

Generic Market Entry: Following patent expiry, several generic pharmaceutical companies have launched or are preparing to launch paliperidone palmitate products. This increases the demand for generic API suppliers and CMOs. The market dynamics are shifting from a single-source innovator product to a multi-supplier generic market.

Regulatory Approvals: Generic versions of paliperidone palmitate require approval from regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This process involves demonstrating bioequivalence to the reference listed drug and ensuring manufacturing processes meet cGMP standards.

Key Takeaways

Johnson & Johnson (Janssen Pharmaceuticals) is the primary innovator and a key manufacturer of paliperidone palmitate API and finished products.
Major generic API manufacturers, including Sun Pharma, Lupin, Dr. Reddy's Laboratories, Teva Pharmaceuticals, and Zydus Lifesciences, are significant players in the global supply chain for paliperidone palmitate API.
Contract Manufacturing Organizations (CMOs) such as Catalent, Lonza, and Patheon are crucial for the sterile formulation and fill-finish operations of paliperidone palmitate drug products.
The manufacturing process is complex, involving multi-step synthesis, precise particle size engineering for controlled release, and sterile aseptic processing.
Supply chain risks include reliance on specific regions for raw materials, regulatory changes, and quality control issues. Mitigation strategies involve dual sourcing and geographical diversification.
The expiry of key patents has opened the market for generic competition, increasing demand for API suppliers and CMOs with expertise in long-acting injectable formulations.

Frequently Asked Questions

Which companies are the primary API manufacturers for paliperidone palmitate? Johnson & Johnson's Janssen Pharmaceuticals is the innovator manufacturer. Major generic API suppliers include Sun Pharma, Lupin, Dr. Reddy's Laboratories, Teva Pharmaceuticals, and Zydus Lifesciences.
What are the critical excipients used in paliperidone palmitate formulations? Critical excipients include suspending agents (e.g., polysorbate 20), emulsifiers, wetting agents, tonicity modifiers (e.g., sodium chloride), and buffering agents, which are essential for creating a stable, long-acting injectable suspension.
What are the main challenges in manufacturing paliperidone palmitate? Manufacturing challenges include the complex multi-step API synthesis, achieving precise particle size distribution for controlled drug release, ensuring sterility during formulation and fill-finish, and managing the global supply chain for raw materials and intermediates.
How does the patent landscape affect the supply of paliperidone palmitate? The expiration of key patents held by the innovator company has paved the way for generic manufacturers to enter the market, increasing the demand for generic API suppliers and CMOs and driving competition in pricing and supply.
What specific regulatory requirements are paramount for paliperidone palmitate manufacturing? Manufacturing must adhere to strict Current Good Manufacturing Practices (cGMP) enforced by regulatory bodies like the FDA and EMA, with a strong emphasis on sterile manufacturing, impurity profiling, particle size control, and demonstration of bioequivalence for generic products.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Orange Book. Retrieved from https://www.fda.gov/drugs/therapeutic-equivalence-dosage-forms/approved-drug-products-and-patents-drug-list-orange-book [2] European Medicines Agency. (n.d.). Public Assessment Reports. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPARs [3] Company Annual Reports and Investor Relations Information (Various Pharmaceutical Companies, including Sun Pharma, Lupin, Dr. Reddy's, Teva, Zydus Lifesciences, Johnson & Johnson). (Accessed 2023-2024). [4] Pharmaceutical Technology and Industry News Outlets (e.g., Fierce Pharma, Pharmaceutical Executive, C&EN). (Ongoing analysis). [5] Lonza Group AG. (n.d.). Services and Capabilities. Retrieved from https://www.lonza.com/ [6] Catalent, Inc. (n.d.). Drug Development and Delivery Solutions. Retrieved from https://www.catalent.com/ [7] Thermo Fisher Scientific. (n.d.). Patheon Services. Retrieved from https://www.thermofisher.com/us/en/home/brands/patheon.html

Suppliers and packagers for generic pharmaceutical drug: PALIPERIDONE PALMITATE